Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
BIOCON | LUPIN | BIOCON / LUPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.9 | 40.2 | 81.7% | View Chart |
P/BV | x | 3.9 | 3.7 | 105.9% | View Chart |
Dividend Yield | % | 0.3 | 0.6 | 42.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
LUPIN Mar-20 |
BIOCON / LUPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 882 | 80.2% | |
Low | Rs | 554 | 505 | 109.7% | |
Sales per share (Unadj.) | Rs | 91.9 | 339.4 | 27.1% | |
Earnings per share (Unadj.) | Rs | 16.7 | -5.9 | -281.0% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 15.5 | 156.3% | |
Dividends per share (Unadj.) | Rs | 1.00 | 6.00 | 16.7% | |
Dividend yield (eoy) | % | 0.2 | 0.9 | 18.3% | |
Book value per share (Unadj.) | Rs | 101.6 | 276.7 | 36.7% | |
Shares outstanding (eoy) | m | 600.00 | 453.00 | 132.5% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 6.9 | 2.0 | 335.7% | |
Avg P/E ratio | x | 37.7 | -116.6 | -32.4% | |
P/CF ratio (eoy) | x | 26.1 | 44.8 | 58.2% | |
Price / Book Value ratio | x | 6.2 | 2.5 | 247.5% | |
Dividend payout | % | 6.0 | -100.9 | -5.9% | |
Avg Mkt Cap | Rs m | 378,330 | 314,201 | 120.4% | |
No. of employees | `000 | 6.1 | 18.3 | 33.5% | |
Total wages/salary | Rs m | 11,653 | 29,868 | 39.0% | |
Avg. sales/employee | Rs Th | 8,994.3 | 8,400.6 | 107.1% | |
Avg. wages/employee | Rs Th | 1,900.7 | 1,632.0 | 116.5% | |
Avg. net profit/employee | Rs Th | 1,635.3 | -147.2 | -1,111.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 153,748 | 35.9% | |
Other income | Rs m | 1,444 | 4,838 | 29.8% | |
Total revenues | Rs m | 56,588 | 158,585 | 35.7% | |
Gross profit | Rs m | 15,883 | 24,849 | 63.9% | |
Depreciation | Rs m | 4,478 | 9,702 | 46.2% | |
Interest | Rs m | 709 | 3,630 | 19.5% | |
Profit before tax | Rs m | 12,140 | 16,355 | 74.2% | |
Minority Interest | Rs m | 9 | 4 | 230.8% | |
Prior Period Items | Rs m | 0 | 39 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | -7,521 | 0.0% | |
Tax | Rs m | 2,123 | 11,571 | 18.3% | |
Profit after tax | Rs m | 10,026 | -2,694 | -372.2% | |
Gross profit margin | % | 28.8 | 16.2 | 178.2% | |
Effective tax rate | % | 17.5 | 70.8 | 24.7% | |
Net profit margin | % | 18.2 | -1.8 | -1,037.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 154,132 | 31.3% | |
Current liabilities | Rs m | 30,376 | 92,252 | 32.9% | |
Net working cap to sales | % | 32.4 | 40.2 | 80.4% | |
Current ratio | x | 1.6 | 1.7 | 95.0% | |
Inventory Days | Days | 68 | 82 | 83.2% | |
Debtors Days | Days | 86 | 129 | 66.1% | |
Net fixed assets | Rs m | 64,130 | 89,082 | 72.0% | |
Share capital | Rs m | 3,000 | 906 | 331.1% | |
"Free" reserves | Rs m | 57,980 | 124,461 | 46.6% | |
Net worth | Rs m | 60,980 | 125,367 | 48.6% | |
Long term debt | Rs m | 15,766 | 17,933 | 87.9% | |
Total assets | Rs m | 121,924 | 249,839 | 48.8% | |
Interest coverage | x | 18.1 | 5.5 | 329.2% | |
Debt to equity ratio | x | 0.3 | 0.1 | 180.7% | |
Sales to assets ratio | x | 0.5 | 0.6 | 73.5% | |
Return on assets | % | 8.8 | 0.4 | 2,350.4% | |
Return on equity | % | 16.4 | -2.1 | -765.1% | |
Return on capital | % | 16.8 | 8.7 | 192.0% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 51,450 | 30.1% | |
Fx outflow | Rs m | 10,399 | 19,470 | 53.4% | |
Net fx | Rs m | 5,107 | 31,980 | 16.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 14,688 | 78.6% | |
From Investments | Rs m | -7,138 | 11,070 | -64.5% | |
From Financial Activity | Rs m | -2,417 | -8,906 | 27.1% | |
Net Cashflow | Rs m | 2,103 | 16,853 | 12.5% |
Indian Promoters | % | 40.4 | 46.6 | 86.7% | |
Foreign collaborators | % | 20.6 | 0.2 | 10,300.0% | |
Indian inst/Mut Fund | % | 8.4 | 11.3 | 74.3% | |
FIIs | % | 10.7 | 31.9 | 33.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 10.1 | 197.0% | |
Shareholders | 109,995 | 98,259 | 111.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: NATCO PHARMA PANACEA BIOTECH FDC GSK PHARMA FRESENIUS KABI ONCO.
Compare BIOCON With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.
More Views on NewsIn this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
A look at what India's top equity mutual funds bought and sold in January 2021.
More